Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

BIODANE PHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 7.1% 7.1%   Bankruptcy risk   10.6% 7.9% 5.7% 4.3% 4.8% 3.5% 16.1% 16.1%   Credit score (0-100)   24 32 40 46 44 52 11 11   Credit rating   BB BB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,011 1,508 1,629 3,701 2,372 3,071 0.0 0.0   EBITDA   -584 338 619 2,360 616 879 0.0 0.0   EBIT   -584 338 619 2,360 616 879 0.0 0.0   Pre-tax profit (PTP)   -598.8 345.4 640.5 2,432.9 751.7 1,154.2 0.0 0.0   Net earnings   -467.1 256.8 499.5 1,897.6 586.4 900.2 0.0 0.0   Pre-tax profit without non-rec. items   -599 345 640 2,433 752 1,154 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   1,402 1,659 2,159 4,056 4,643 3,543 119 119   Interest-bearing liabilities   0.0 0.0 0.0 0.0 446 146 0.0 0.0   Balance sheet total (assets)   1,477 1,775 2,427 5,033 5,351 4,283 119 119   Net Debt   -156 -189 -261 -750 426 -215 -119 -119     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,011 1,508 1,629 3,701 2,372 3,071 0.0 0.0   Gross profit growth   4.5% 49.2% 8.0% 127.2% -35.9% 29.5% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,477 1,775 2,427 5,033 5,351 4,283 119 119   Balance sheet change%   -28.5% 20.2% 36.7% 107.4% 6.3% -20.0% -97.2% 0.0%   Added value   -583.8 337.5 618.6 2,360.0 616.2 878.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 1.0 2.0 3.0 4.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -57.8% 22.4% 38.0% 63.8% 26.0% 28.6% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -32.2% 22.8% 31.8% 65.9% 15.1% 24.4% 0.0% 0.0%   ROI %   -34.8% 24.2% 35.0% 79.2% 17.1% 26.8% 0.0% 0.0%   ROE %   -28.6% 16.8% 26.2% 61.1% 13.5% 22.0% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   95.0% 93.5% 89.0% 80.6% 86.8% 82.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   26.7% -56.0% -42.2% -31.8% 69.2% -24.5% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 9.6% 4.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 13.4% 7.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   17.7 13.5 8.3 4.9 7.1 5.4 0.0 0.0   Current Ratio   19.9 15.3 9.1 5.2 7.6 5.8 0.0 0.0   Cash and cash equivalent   156.2 189.1 261.2 750.0 19.6 361.8 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,402.2 1,659.0 2,158.5 4,056.2 4,642.5 3,542.8 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -584 338 619 2,360 616 879 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -584 338 619 2,360 616 879 0 0   EBIT / employee   -584 338 619 2,360 616 879 0 0   Net earnings / employee   -467 257 500 1,898 586 900 0 0